BACKGROUND: Beta thalassemia major requires regular blood transfusions and iron chelation to alleviate the harmful accumulation of iron. Evidence on the efficacy and safety of the available agents, desferrioxamine and deferiprone, is derived from small, non-comparative, heterogeneous observational studies. This evidence was reviewed to quantitatively compare the ability of these chelators to re...

Pantothenate kinase-associated neurodegeneration (PKAN) is the most common form of neurodegeneration with brain iron accumulation, it is an autosomal recessive disease due to mutation in PANK 2 on chromosome 20, which causes the accumulation of iron in basal ganglia and production of free radicals that cause degeneration of the cells. Deferiprone is an iron chelator that was used in treatment o...

Most deaths in beta-thalassemia major result from cardiac complications due to iron overload. Differential effects on myocardial siderosis may exist between different chelators. A randomized controlled trial was performed in 61 patients previously maintained on subcutaneous deferoxamine. The primary end point was the change in myocardial siderosis (myocardial T2*) over 1 year in patients mainta...

introduction: the best and effective iron chelation remain one of the major strategy in clinical management of thalassemia major patients. the purpose of this study was to evaluate the safety and effectiveness of combined therapy with desferrioxamine and deferiprone in patients with thalassemia major that undergoing in regular administration of adequate desferrioxamine (5-6 days/week). patients...

A comparative study of the iron-clearing properties of subcutaneously (SC) administered deferoxamine (DFO) with those of orally administered 1,2-dimethyl-3-hydroxypyrid-4-one (CP20) and 1.2-diethyI-3-hydroxypyrid-4-one (CP94) is presented. The studies were performed in both a non-ironoverloaded, bile duct-cannulated rat model and an ironloaded Cebus monkey model. All three drugs performed well ...

Malaventura C, et al. Deferasirox, deferiprone and desferrioxamine treatment in thalassemia major patients: cardiac iron and function comparison determined by quantitative magnetic resonance imaging. Comparison of effects of oral deferiprone and subcutaneous desfer-rioxamine on myocardial iron concentrations and ventricular function in beta-thalassaemia. Effects of chelation therapy on cardiac ...

3-Hydroxy-1,2-dimethylpyridin-4(1H)-one (deferiprone) is a successful iron chelator, which has been widely investigated for its activity in mitigating iron overload and in protecting against oxidative stress due to Reactive Oxygen Species (ROS). Herein, we present the synthesis, characterisation, physicochemical properties and antioxidant activity of two novel bioconjugates of β-cyclodextrin be...

although successful iron chelation with deferiprone is associated with significant complications, patient’s compliance with medication regimens is of a high priority. the present study did evaluate the complications and compliance of domestically-manufactured deferiprone combined with desferrioxamine for iron chelation therapy. a total of 32 major beta thalassemic patients with cardiomyopathy w...

Parkinson’s Disease (PD) is a common and progressive neurodegenerative disorder characterised by motor impairments as well non-motor symptoms. While dopamine-based therapies are effective in fighting the symptoms early stages of disease, lack neuroprotective drugs means that disease continues to progress. Along with traditionally recognised pathological hallmarks dopaminergic neuronal death int...

a sensitive fluorometric method for the determination of deferiprone (dfp) based on the formation of a luminescent complex with tb3+ ions in aqueous solutions is reported. the maximum excitation and emission wavelengths were 295 and 545 nm, respectively. the effects of various factors on the luminescence intensity of the system were investigated and optimized, then under the optimum conditions,...